Shah VN, Peters AL, Umpierrez GE, Sherr JL, Akturk HK, Aleppo G, Bally L, Cengiz E, Cinar A, Dungan K, Fabris C, Jacobs PG, Lal RA, Mader JK, Masharani U, Prahalad P, Schmidt S, Zijlstra E, Ho CN, Ayers AT et al (2025) Consensus report on glucagon-like peptide-1 receptor agonists as adjunctive treatment for individuals with type 1 diabetes using an automated insulin delivery system
OptioRx is a smaller pharmacy partner, so state availability may be more limited
Based on the known effects of GLP-1 and glucagon receptor agonism on hepatic fat metabolism and insulin sensitivity, there is a plausible mechanistic rationale for benefit
EMAN2: An extensible image processing suite for electron microscopy
Adjusted scores based on new data
[PMID: 40791813] PubMed record related to this compound for laboratory literature review